In clinical trials, many patients who took Semaglutide lost a significant amount of weight, which can help improve overall health and reduce the risk of chronic diseases
SD 2.9) and PROMIS-10 GPH (47.0
Clinical implication: clinicians should treat vaginal symptoms in patients taking semaglutide as real and addressable , but approach causality cautiously: prioritise common diagnoses (genitourinary syndrome of menopause, infections, dermatologic vulvar disease, STIs, irritant/contact dermatitis, pelvic floor disorders), identify important confounders (notably SGLT2 inhibitors, antibiotics, hormonal therapies), manage symptoms and underlying conditions, and report suspected adverse reactions when there is a reasonable temporal relationship and alternative causes are less likely
All the health care services we pay for and we pay an average of $100 million per day are factored into the future premiums and administrative fees we charge